Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of NVX‐207, a novel betulinic acid‐derived anti‐cancer compound

20 Mar 2009

Abstract excerpt

BACKGROUND: Development of betulinic acid derivatives for clinical use has been hampered by adverse pharmacological and physico-chemical characteristics of this class of compounds. We here present a novel semi-synthetic betulinic acid-derived drug candidate well suited for further clinical development. MATERIALS AND METHODS: In vitro activity and mode of action of NVX-207 were determined using normal as well as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Metabolism and Diseases
Share to Flavonoids in Medical Research
Share to Natural product bioactivities and synthesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19309323
DOI: 10.1111/j.1365-2362.2009.02105.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of NVX‐207, a novel betulinic acid‐derived anti‐cancer compoundPMID 19309323Read ↗

Acetyl-cinobufagin Suppresses Triple Negative Breast Cancer Progression by Inhibiting the STAT3 PathwaySemantic proximity Read ↗

A robust screening method for dietary agents that activate tumour-suppressor microRNAs.Semantic proximity Read ↗

Discovery of Canine Drug Toceranib Phosphate as a Repurposed Agent against Human Hepatocellular CarcinomaSemantic proximity Read ↗

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain AntagonistSemantic proximity Read ↗

The Rexinoid V-125 Reduces Tumor Growth in Preclinical Models of Breast and Lung CancerSemantic proximity Read ↗

Tubulin-Interactive Natural Products as Anticancer AgentsSemantic proximity Read ↗

Anticancer genes (NOXA, PAR-4, TRAIL) are de-regulated in breast cancer patients and can be targeted by using a ribosomal inactivating plant protein (riproximin)Semantic proximity Read ↗

High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma CellsSemantic proximity Read ↗

(−)-Xanthatin Selectively Induces GADD45γ and Stimulates Caspase-Independent Cell Death in Human Breast Cancer MDA-MB-231 CellsSemantic proximity Read ↗

Discovery of Benzo[<i>cd</i>]indol-2(1<i>H</i>)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological EvaluationSemantic proximity Read ↗

Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural productSemantic proximity Read ↗

EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells <i>in vivo</i> and <i>in vitro</i>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.